EE03383B1 - Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon - Google Patents

Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Info

Publication number
EE03383B1
EE03383B1 EE9400341A EE9400341A EE03383B1 EE 03383 B1 EE03383 B1 EE 03383B1 EE 9400341 A EE9400341 A EE 9400341A EE 9400341 A EE9400341 A EE 9400341A EE 03383 B1 EE03383 B1 EE 03383B1
Authority
EE
Estonia
Prior art keywords
inhibitor
cholesterol
pct
combination
lactam
Prior art date
Application number
EE9400341A
Other languages
English (en)
Estonian (et)
Other versions
EE9400341A (et
Inventor
R. Davis Harry
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE9400341A publication Critical patent/EE9400341A/xx
Publication of EE03383B1 publication Critical patent/EE03383B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
EE9400341A 1992-12-23 1994-11-23 Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon EE03383B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (2)

Publication Number Publication Date
EE9400341A EE9400341A (et) 1996-04-15
EE03383B1 true EE03383B1 (et) 2001-04-16

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400341A EE03383B1 (et) 1992-12-23 1994-11-23 Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Country Status (32)

Country Link
US (1) US5661145A (no)
EP (1) EP0675714B1 (no)
JP (1) JP3992728B2 (no)
KR (1) KR100306936B1 (no)
CN (1) CN1090479C (no)
AT (1) ATE175872T1 (no)
AU (1) AU680864B2 (no)
CA (1) CA2152351C (no)
CZ (1) CZ287125B6 (no)
DE (1) DE69323213T2 (no)
DK (1) DK0675714T3 (no)
EE (1) EE03383B1 (no)
ES (1) ES2128552T3 (no)
FI (1) FI952916A0 (no)
GR (1) GR3029405T3 (no)
HR (1) HRP931515B1 (no)
HU (1) HU221724B1 (no)
IL (1) IL108112A (no)
LT (1) LT3300B (no)
LV (1) LV10919B (no)
MX (1) MX9308053A (no)
MY (1) MY109538A (no)
NO (1) NO311325B1 (no)
NZ (1) NZ259790A (no)
PL (1) PL174128B1 (no)
SG (1) SG45147A1 (no)
SI (1) SI9300677A (no)
SK (1) SK281173B6 (no)
TW (1) TW319698B (no)
WO (1) WO1994014433A1 (no)
YU (1) YU49060B (no)
ZA (1) ZA939552B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996009827A2 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
KR20040029459A (ko) 1995-11-02 2004-04-06 워너-램버트 캄파니 엘엘씨 지질 농도를 조절하는 제약 조성물 및 방법
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
WO2000063703A1 (en) * 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CN1915429B (zh) * 2001-01-26 2010-12-15 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
CZ304929B6 (cs) 2001-03-28 2015-01-28 Merck Sharp & Dohme Corp. Enantioselektivní syntéza azetidinonových meziproduktů
US20030119757A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
DK1429756T3 (da) * 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
ES2318274T3 (es) * 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
JP5137228B2 (ja) * 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2007516287A (ja) * 2003-12-23 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血症化合物
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
EP1723414A4 (en) * 2004-01-16 2008-03-26 Merck & Co Inc NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
AR049655A1 (es) * 2004-07-01 2006-08-23 Schering Corp Antagonistas de nk1
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
CA2610959A1 (en) 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
MX2009002398A (es) * 2006-09-05 2009-03-16 Schering Corp Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN102448456A (zh) 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
JP2525125B2 (ja) * 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
US9205972B2 (en) 2012-01-26 2015-12-08 Intralot S.A.—Integrated Lottery Systems and Services Methods and systems for dispensing

Also Published As

Publication number Publication date
AU680864B2 (en) 1997-08-14
EP0675714B1 (en) 1999-01-20
NO952529L (no) 1995-06-23
FI952916A (fi) 1995-06-14
IL108112A0 (en) 1994-04-12
LV10919B (en) 1996-04-20
AU5872094A (en) 1994-07-19
HRP931515A2 (en) 1996-12-31
YU80293A (sh) 1997-12-05
FI952916A0 (fi) 1995-06-14
CZ164395A3 (en) 1996-03-13
ES2128552T3 (es) 1999-05-16
DE69323213D1 (de) 1999-03-04
LTIP1514A (en) 1994-10-25
IL108112A (en) 1999-11-30
HRP931515B1 (en) 2000-02-29
LV10919A (lv) 1995-12-20
US5661145A (en) 1997-08-26
GR3029405T3 (en) 1999-05-28
TW319698B (no) 1997-11-11
JPH08505141A (ja) 1996-06-04
NO952529D0 (no) 1995-06-23
CA2152351A1 (en) 1994-07-07
YU49060B (sh) 2003-08-29
MY109538A (en) 1997-02-28
HU221724B1 (hu) 2002-12-28
KR100306936B1 (ko) 2001-11-30
LT3300B (en) 1995-06-26
CN1090479C (zh) 2002-09-11
CN1095591A (zh) 1994-11-30
SK78395A3 (en) 1996-05-08
HUT72081A (en) 1996-03-28
MX9308053A (es) 1994-06-30
SG45147A1 (en) 1998-01-16
HU9501854D0 (en) 1995-08-28
ZA939552B (en) 1994-10-12
SI9300677A (en) 1994-09-30
ATE175872T1 (de) 1999-02-15
SK281173B6 (sk) 2000-12-11
EP0675714A1 (en) 1995-10-11
CA2152351C (en) 2009-09-22
EE9400341A (et) 1996-04-15
CZ287125B6 (en) 2000-09-13
NZ259790A (en) 1997-02-24
PL309636A1 (en) 1995-10-30
DK0675714T3 (da) 1999-09-13
WO1994014433A1 (en) 1994-07-07
DE69323213T2 (de) 1999-07-08
JP3992728B2 (ja) 2007-10-17
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30

Similar Documents

Publication Publication Date Title
EE03383B1 (et) Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon
GEP20033006B (en) Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
AU2483000A (en) Treatment of asthma with mek inhibitors
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
AU4923093A (en) Inhibitors of metazoan parasite proteases
EP0646007A4 (no)
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
AU9066498A (en) Substituted 6-alkylphenanthridines
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
DE69717277D1 (en) Imidazopyridine
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111123